Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
New Treatments for Myelofibrosis
Douglas Tremblay
, Ruben Mesa
Icahn School of Medicine at Mount Sinai
Research output
:
Contribution to journal
›
Article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New Treatments for Myelofibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myelofibrosis
100%
JAK Inhibitors
60%
Telomerase
20%
Pathophysiology
20%
Therapeutic Potential
20%
Bcl-xL
20%
B-cell Lymphoma 2 (Bcl-2)
20%
Unmet Needs
20%
Clinical Development
20%
Targeted Treatment
20%
Symptom Burden
20%
Phosphoinositide 3-kinase (PI3K)
20%
Spleen Size
20%
Rapid Development
20%
Suboptimal Response
20%
Intolerance
20%
Combination Treatment
20%
CD123
20%
JAK-STAT Pathway
20%
LSD1
20%
Meaningful Improvement
20%
HDM2
20%
PIM-1
20%
Leukemic Progression
20%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Janus Kinase Inhibitor
60%
Pathophysiology
20%
Telomerase
20%
JAK-STAT Signaling
20%